Generate Biomedicines stock
GENBNASDAQGenerate Biomedicines, Inc., HealthcareISIN US3709201004
38Score 38 out of 100, Weak
Price and trend
85 / 100
Price history
−0.6% since 2026The chart shows daily closing prices since 27 Feb 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 38% below its 52-week high. Largest decline since 27 Feb 2026: 41% (August 2026 to October 2026).
Chart figures for advanced users
- SMA 50$14.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.21
- The lowest closing price of the last twelve months.
- Resistance$20.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Generate Biomedicines, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.61B, is number 144 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $31.89M (up 55.9% year on year) and a loss of $203.15M.
- For fiscal 2026, analysts expect on average revenue of $29.68M (down 6.9%) and adjusted earnings per share of −$2.28.
Show more
- MEQIRI Score 38 out of 100 (Weak): rank 576 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $457.42M, financial debt $62.63M.Stability 53
Weaknesses
- Loss-makingLoss of $237.74M over the last 12 months.Fundamentals 10
- Volatile share priceVolatility 88% a year over the last 12 months.Stability 53
- Negative free cash flowFree cash flow −$244.35M over the last 12 months.Fundamentals 10
Its standout strength is technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 37 to 38.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Jun 2026, revenue fell 37.7% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 56% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −737%, net −637%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$0.68 (expected −$0.56)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.280.0%
- Revenue
- $29.68M0.0%
- Earnings per share
- −$2.300.0%
- Revenue
- $23.83M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $200,735 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Generate Biomedicines
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Sarepta TherapeuticsSRPT $1.79B40
- Nurix TherapeuticsNRIX $1.78B69
- MesoblastMESO $1.77B39
- AbsciABSI $1.74B40
- uniQureQURE $1.72B36
- Ultragenyx PharmaceuticalRARE $1.7B38
- SELLAS Life Sciences GroupSLS $1.7B36
- PrecigenPGEN $1.69B55
ETFs that hold Generate Biomedicines
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.